Search Results
Oct 28, 2025, 14:17 ET Duffy & Shanley Wins Top Award at the 2025 PRNEWS Platinum Awards Gala
"This year's winners exemplify the creativity, integrity and strategic excellence driving our industry forward. The evening was a true celebration of PR's power to connect with one another, inspire and make an impact." The gala featured a red-carpet networking reception, seated dinner,
More news about: Duffy & Shanley
Oct 27, 2025, 07:00 ET Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial
fibrosis. Bersiporocin is a first-in-class, orally administered antifibrotic therapy that selectively inhibits prolyl-tRNA synthetase (PRS) — a key enzyme involved in collagen synthesis. By directly blocking this pathway, Bersiporocin is designed to halt fibrosis at its origin, potentially
More news about: Daewoong Pharmaceutical Co., Ltd.
Oct 23, 2025, 19:30 ET HanchorBio Presents Phase 1 HCB101 Clinical Results at FACO 2025 Demonstrating Safety and Early Antitumor Activity
achieved at doses ≥1.28 mg/kg. Encouraging antitumor activity: Two confirmed partial responses (PRs) in head and neck squamous cell carcinoma (HNSCC) and non-Hodgkin lymphoma, alongside durable disease control in multiple patients.
More news about: HanchorBio Inc.
Oct 23, 2025, 07:00 ET HanchorBio's Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology
in tumor size in the dose cohort. At 5.12 mg/kg, all three evaluable patients achieved confirmed PRs (33%–46% tumor reductions). At 8.0 mg/kg, all three evaluable patients have now achieved confirmed PRs (tumor shrinkage up to -78%) after extended follow-up. Together, these results represent a
More news about: HanchorBio Inc.
Oct 20, 2025, 04:30 ET Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
>20%), the 2.4 mg/kg dose cohort observed 1 CR, 11 PRs and 15 SDs, resulting in 40% ORR (12/30) and 90% DCR (27/30). The median PFS was 6.97 months and the 12-month OS rate was 66.2%. In the 1.8 mg/kg dose cohort, there were 1 CR, 9 PRs, and 11 SDs, giving a 40% ORR (10/25) and 84% DCR (21/25).
More news about: Antengene Corporation Limited
Oct 19, 2025, 21:00 ET Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
patients with moderate/high CLDN18.2 expression (IHC 2+ > 20%), the 2.4 mg/kg dose cohort observed 1 complete response (CR), 11 partial responses (PRs) and 15 stable diseases (SDs), resulting in an objective response rate (ORR) of 40% (12/30) and a disease control rate (DCR) of 90% (27/30). The median
More news about: Antengene Corporation Limited
Oct 18, 2025, 01:00 ET SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025
(DCR) of 100%. Four of the seven patients (57%) achieved >30% tumor reduction, including two confirmed partial responses (PR) and two unconfirmed PRs. No dose-limiting toxicities or serious adverse events were reported. These preliminary findings support continued clinical development of SCG142.
More news about: SCG Cell Therapy Pte Ltd
Oct 18, 2025, 01:00 ET SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025
(DCR) of 100%. Four of the seven patients (57%) achieved >30% tumor reduction, including two confirmed partial responses (PR) and two unconfirmed PRs. No dose-limiting toxicities or serious adverse events were reported. These preliminary findings support continued clinical development of SCG142.
More news about: SCG Cell Therapy Pte Ltd
Oct 16, 2025, 07:10 ET CMC REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2025 RESULTS
Performance Reinforcing Steel ("PRS") also improved on a year-over-year basis. Net sales and margins within CMC Construction Services benefited from initiatives to standardize commercial practices and grow store traffic, while strong project-related demand continued to propel PRS performance. Indications
More news about: Commercial Metals Company
Oct 14, 2025, 12:00 ET Mabwell Announces Latest Clinical Results of Novel B7-H3-Targeting ADC 7MW3711 to Be Presented at 2025 ESMO Congress
and treated with 7MW3711 in the phase I/II study. Among 54 patients treated at 4.0 mg/kg or above and reaching tumor assessment, 19 partial responses (PRs) or complete responses (CRs) were observed. 7 patients with esophageal cancer (EC) were enrolled at 4.0 mg/kg or above and achieved an objective response
More news about: Mabwell
Oct 14, 2025, 04:00 ET ILIKOS and Zapyrus have partnered to equip MedTech CRO business development teams with the tools and insights to win high-value opportunities in a competitive global market
and conduct tactical outreach. Zapyrus covers medical device, IVD, SaMD company intel around the globe. It's a one stop shop for clinical data, public PRs, financial data, and proprietary machine learning predictability data. "At Zapyrus, our mission is to empower business development
More news about: ILIKOS Consulting Group
Oct 10, 2025, 13:00 ET Illumination PR Expands into Healthcare Communications with the Launch of DR Media Group
communications division—created to serve doctors, medical practices, and med spas with the same creativity and impact that have defined Illumination PR's success.
More news about: ILLUMINATION PR
Oct 09, 2025, 06:00 ET Allelica Launches AbsoluteDx: The Most Comprehensive Genetic Risk Assessment, Combining Monogenic and Polygenic Insights Across Multiple Diseases
a precision medicine company specializing in multi-ancestry polygenic risk scores (PRS) to predict genetic risk for common diseases in diverse populations. By integrating advanced bioinformatics with multi-ancestry PRS, Allelica empowers physicians and healthcare systems to reduce the burden of common
More news about: Allelica, Inc.
Oct 08, 2025, 12:00 ET Cloud Native Computing Foundation Announces Knative's Graduation
into a single Steering Committee by Dec 2024, and defined annual elections and the maintainer lifecycle, documented contribution processes (issues, PRs, and working groups). Further, Knative completed audits and reviews to ensure standards such as a General Technical Review with TAG Runtime & App
More news about: Cloud Native Computing Foundation
Oct 07, 2025, 09:00 ET The Abbi Agency Named Agency of Record For the Nevada Mining Association
Recently named Advertising Agency of the Year by the American Advertising Federation's (AAF) Western Region Best of the West Media Awards and Bulldog PR's Midsize Agency of the Year, the agency excels in creating award-winning integrated marketing campaigns for clients, including Visit Carmel, Carnival
More news about: Nevada Mining Association
Oct 06, 2025, 16:23 ET Largest Study to Date Shows Plastic Surgery Medical Tourism Can Match -- or Surpass -- U.S. Safety Benchmarks
CARTAGENA, Colombia, Oct. 6, 2025 /PRNewswire/ -- A landmark study published in PRS Global Open finds that plastic surgery medical tourism, when performed in accredited, high-volume centers, can be as safe — and sometimes safer —
More news about: Premium Care Plastic Surgery
Oct 02, 2025, 16:31 ET Town of Taos Selects The Abbi Agency as PR/Marketing Agency of Record
Recently named Advertising Agency of the Year by the American Advertising Federation's (AAF) Western Region Best of the West Media Awards and Bulldog PR's Midsize Agency of the Year, the agency excels in creating award-winning integrated marketing campaigns for clients, including Aramark Destinations,
More news about: The Abbi Agency
Oct 02, 2025, 09:00 ET Bolt PR Named Winner in PR Daily's 2025 Social Media & Digital Awards
Bolt PR's winning entry, Bolt PR Drives Massive SEO Growth for ART Surgical, was recognized for its innovative, content-driven approach that pushed 6,836
More news about: Bolt PR
Sep 30, 2025, 08:30 ET PR Veteran Jacqueline Agudelo Launches Jack Public Relations to Bring Executive-Level Strategy to Startups, VCs, and Legacy Brands
these innovations into a successful PR strategy," stated James Lamberti, Head of Go-To-Market, Georgian. Georgian is one of Jack PR's flagship accounts, helping manage external communications, content development for strategic thought leadership, media training, reputational communication
More news about: Jack Public Relations
Sep 25, 2025, 20:47 ET Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth
inhibitor JAB-23E73 has shown important progress. In the dose-escalation phase of its Phase I clinical trial, multiple confirmed partial responses (PRs) have been observed, with favorable safety and pharmacokinetic (PK) profiles consistent with expectations. Full Phase I data are expected to be released
More news about: Jacobio Pharma
Sep 24, 2025, 09:24 ET Fishman Public Relations Ranked No. 1 Franchise PR Agency in Entrepreneur for 8th Consecutive Year
This remarkable eight-year streak cements Fishman PR's reputation as the undisputed leader in franchise PR and marketing, a role the agency has proudly upheld for more than three decades. Since its founding
More news about: Fishman Public Relations, Inc.
Sep 12, 2025, 07:02 ET Ripley PR launches Adventure PR to amplify adventure travel, RV and outdoor brands
impactful earned media placements and capturing the imagination of travelers seeking experiences off the beaten path. Adventure PR builds on Ripley PR's reputation as the leading agency in the home services industry. Just as many RVs serve as full-time homes or vacation getaways, the agency will apply
More news about: Ripley PR